Analysis of ATROSAB for binding to human soluble Fcγ receptors and human complement protein C1q and the lack of the induction of ADCC and CDC.

<p>Binding of immobilized ATROSAB and Trastuzumab to human soluble Fcγ receptor IA (a), Fcγ receptor IIB (b), Fcγ receptor IIIA (c), and human C1q (d). e) ADCC of ATROSAB and an anti-CD20 monoclonal antibody Rituximab on Kym-1 cells and DOHH-2 cells, respectively, using different effector to target cell ratios (n = 4). f) CDC of ATROSAB and Rituximab on Kym-1 cells and DOHH-2 cells, respectively, using serum from two different donors and various serum dilutions (n = 4). Asterisks indicate statistically significant differences (** p<0.01, *** p<0.001).